Metabolic Effects of Metformin Therapy in Obstructive Sleep Apnea
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to see if metformin improves metabolism in patients with
obstructive sleep apnea (OSA) using positive airway pressure (PAP) therapy. Metformin is
approved by the Food and Drug Administration (FDA) for the treatment and prevention of
diabetes. It is not approved for use in patients with OSA.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Pennington Biomedical Research Center
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)